Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.

Journal Article (Clinical Trial;Journal Article)

RO4929097 is a potent and selective inhibitor of γ-secretase and as a result is able to inhibit Notch pathway signaling. The activity of RO4929097 was evaluated against the in vivo panels of the Pediatric Preclinical Testing Program (PPTP). RO4929097 induced significant differences in event-free survival (EFS) distribution compared to control in 6 of 26 (23%) of the evaluable solid tumor xenografts and in 0 of 8 (0%) of the evaluable ALL xenografts. The most consistent tumor growth delay effects were noted in the osteosarcoma panel. RO4929097 at the dose and schedule evaluated demonstrated little antitumor activity against childhood cancer xenografts.

Full Text

Duke Authors

Cited Authors

  • Kolb, EA; Gorlick, R; Keir, ST; Maris, JM; Lock, R; Carol, H; Kurmasheva, RT; Reynolds, CP; Kang, MH; Wu, J; Houghton, PJ; Smith, MA

Published Date

  • May 2012

Published In

Volume / Issue

  • 58 / 5

Start / End Page

  • 815 - 818

PubMed ID

  • 22052798

Pubmed Central ID

  • PMC3276746

Electronic International Standard Serial Number (EISSN)

  • 1545-5017

Digital Object Identifier (DOI)

  • 10.1002/pbc.23290

Language

  • eng

Conference Location

  • United States